JP7555542B2 - 統合失調症及び他の神経精神障害の治療方法 - Google Patents
統合失調症及び他の神経精神障害の治療方法 Download PDFInfo
- Publication number
- JP7555542B2 JP7555542B2 JP2020570726A JP2020570726A JP7555542B2 JP 7555542 B2 JP7555542 B2 JP 7555542B2 JP 2020570726 A JP2020570726 A JP 2020570726A JP 2020570726 A JP2020570726 A JP 2020570726A JP 7555542 B2 JP7555542 B2 JP 7555542B2
- Authority
- JP
- Japan
- Prior art keywords
- rest
- therapeutic composition
- glial
- cells
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043444A JP2024075673A (ja) | 2018-06-18 | 2024-03-19 | 統合失調症及び他の神経精神障害の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686346P | 2018-06-18 | 2018-06-18 | |
| US62/686,346 | 2018-06-18 | ||
| PCT/US2019/037754 WO2019246112A1 (en) | 2018-06-18 | 2019-06-18 | Methods of treating schizophrenia and other neuropsychiatric disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043444A Division JP2024075673A (ja) | 2018-06-18 | 2024-03-19 | 統合失調症及び他の神経精神障害の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529169A JP2021529169A (ja) | 2021-10-28 |
| JP2021529169A5 JP2021529169A5 (cg-RX-API-DMAC7.html) | 2022-05-19 |
| JP7555542B2 true JP7555542B2 (ja) | 2024-09-25 |
Family
ID=67297259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570726A Active JP7555542B2 (ja) | 2018-06-18 | 2019-06-18 | 統合失調症及び他の神経精神障害の治療方法 |
| JP2024043444A Pending JP2024075673A (ja) | 2018-06-18 | 2024-03-19 | 統合失調症及び他の神経精神障害の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043444A Pending JP2024075673A (ja) | 2018-06-18 | 2024-03-19 | 統合失調症及び他の神経精神障害の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3806861A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7555542B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102847197B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112566640A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3103663A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019246112A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120754249A (zh) * | 2021-09-30 | 2025-10-10 | 上海鲸奇生物科技有限公司 | 直接转分化治疗神经系统疾病 |
| US20230241118A1 (en) * | 2021-10-20 | 2023-08-03 | University Of Rochester | Rejuvenation treatment of age-related white matter loss |
| EP4674962A1 (en) * | 2023-02-28 | 2026-01-07 | The University of Osaka | Oligonucleotide, and rest expression suppressing agent and pharmaceutical composition using same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5935811A (en) | 1995-03-03 | 1999-08-10 | California Institute Of Technology | Neuron-restrictive silencer factor nucleic acids |
| US20080119427A1 (en) | 1996-06-06 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| BRPI0008131B8 (pt) | 1999-02-12 | 2021-05-25 | Daiichi Sankyo Co Ltd | composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US20030027153A1 (en) * | 2001-01-09 | 2003-02-06 | Meyer Joanne M. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| EP1857547B2 (en) | 2002-08-05 | 2020-12-02 | Silence Therapeutics GmbH | Further novel forms of interfering RNA molecules |
| EP1393776A1 (en) * | 2002-08-14 | 2004-03-03 | Erasmus University Medical Center Rotterdam | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| EP2182063A3 (en) | 2003-09-18 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Modulation of EIF4E expression |
| JP4428296B2 (ja) | 2005-06-10 | 2010-03-10 | セイコーエプソン株式会社 | 表示パネルモジュールおよび表示装置 |
| EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
| DK3399025T3 (da) | 2007-03-23 | 2025-06-16 | Wisconsin Alumni Res Found | Omprogrammering af somatiske celler |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| EP2195029A2 (en) | 2007-08-24 | 2010-06-16 | Oryzon Genomics SA | Treatment and prevention of neurodegenerative diseases |
| EP2315829B1 (en) | 2008-08-08 | 2015-02-11 | Mayo Foundation For Medical Education And Research | Induced pluripotent stem cells |
| WO2011031998A1 (en) * | 2009-09-11 | 2011-03-17 | Isis Pharmaceuticals, Inc. | Modulation of re1 silencing transcription factor expression |
| WO2011062963A2 (en) | 2009-11-17 | 2011-05-26 | Vitro Diagnositics, Inc. | Induced puripotent stem cells and related methods |
| US9005967B2 (en) | 2010-01-22 | 2015-04-14 | Kyoto University | Myc variants improve induced pluripotent stem cell generation efficiency |
| KR101235256B1 (ko) * | 2010-09-13 | 2013-02-21 | 서울대학교산학협력단 | miRNA를 타겟으로 한 신경퇴행성 질환 치료 |
-
2019
- 2019-06-18 CN CN201980053363.2A patent/CN112566640A/zh active Pending
- 2019-06-18 JP JP2020570726A patent/JP7555542B2/ja active Active
- 2019-06-18 CA CA3103663A patent/CA3103663A1/en active Pending
- 2019-06-18 KR KR1020217001589A patent/KR102847197B1/ko active Active
- 2019-06-18 EP EP19740110.2A patent/EP3806861A1/en active Pending
- 2019-06-18 WO PCT/US2019/037754 patent/WO2019246112A1/en not_active Ceased
-
2024
- 2024-03-19 JP JP2024043444A patent/JP2024075673A/ja active Pending
Non-Patent Citations (3)
| Title |
|---|
| Mol. Neurobiol.,2017年,Vol.54,pp.541-550,DOI 10.1007/s12035-015-9658-4 |
| Pharmacol. Rev.,2013年,Vol.65,pp.105-142,http://dx.doi.org/10.1124/pr.111.005512 |
| STEM CELLS,2013年,Vol.31,pp.1816-1828 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021529169A (ja) | 2021-10-28 |
| CA3103663A1 (en) | 2019-12-26 |
| US20210260002A1 (en) | 2021-08-26 |
| EP3806861A1 (en) | 2021-04-21 |
| KR102847197B1 (ko) | 2025-08-20 |
| CN112566640A (zh) | 2021-03-26 |
| WO2019246112A1 (en) | 2019-12-26 |
| JP2024075673A (ja) | 2024-06-04 |
| KR20210056324A (ko) | 2021-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7518547B2 (ja) | 統合失調症及び他の神経精神障害の治療方法 | |
| JP2024075673A (ja) | 統合失調症及び他の神経精神障害の治療方法 | |
| JP2024023379A (ja) | ハンチントン病を治療するまたはその発症を阻害する方法 | |
| US20180312839A1 (en) | Methods and compositions for increasing smn expression | |
| JP2021520200A (ja) | 非神経細胞のニューロンへの再プログラミング、及び神経変性疾患または障害を治療するための方法と組成物 | |
| US20150299698A1 (en) | Methods for engineering non-neuronal cells into neurons and using newly engineered neurons to treat neurodegenerative diseases | |
| WO2012008301A1 (ja) | siRNA導入による新規hiPSC作製法 | |
| EP3987030A2 (en) | Ppm1a inhibitors and methods of using same | |
| JP2018531046A6 (ja) | 核酸ベースのtia−1阻害剤 | |
| JP2018531046A (ja) | 核酸ベースのtia−1阻害剤 | |
| CN105101951B (zh) | 一种用于基因-药物治疗的新型试剂 | |
| US10537591B2 (en) | Method for promoting muscle regeneration | |
| US20240409890A1 (en) | Ufmylation inhibition to target tauopathy in human neurons | |
| US20190055553A1 (en) | Methods for identifying and targeting non-coding rna scaffolds | |
| US20260022377A1 (en) | Polynucleotide compositions and methods for treatment of neurodegenerative diseases | |
| WO2025155251A1 (en) | Methods of treating dystrophinopathies | |
| WO2025079278A1 (ja) | シャルコー・マリー・トゥース病の処置剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220511 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230821 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240319 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240501 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240528 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240805 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240903 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7555542 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |